XtalPi Holdings (2228) H2 2025 earnings summary

Executive summary

• Achieved first full-year profitability in 2025, with revenue up 201% year-over-year to RMB 803 million and adjusted net profit of RMB 258 million, reversing a prior loss.

• Significant expansion in customer base, including 17 of the world's top 20 pharma companies as clients, and successful entry into new verticals such as consumer health and new materials.

• Major technological advancements in AI, robotics, and multi-agent systems, driving efficiency and innovation across R&D workflows.

Financial highlights

• Revenue rose to RMB 803 million in 2025 from RMB 266 million in 2024, a 201% increase year-over-year.

• R&D expenses increased 36% to RMB 569 million.

• Net profit reached RMB 135 million, compared to a loss of RMB 1,515 million in 2024.

• Adjusted net profit (non-IFRS) was RMB 258 million, up from a loss of RMB 457 million.

• Cash balance as of December 31, 2025, was RMB 7,069 million, up 126% year-over-year.

Outlook and guidance

• Continued expansion into consumer health, new materials, and agriculture, with plans to further leverage AI-driven platforms for growth.

• Ongoing investment in AI, robotics, and data platforms to sustain innovation and operational efficiency.